PALMIRA
Phase II PALMIRA: Second-line ET ± Palbociclib Maintenance in Patients With HR+/HER2- Advanced Breast Cancer After Clinical Benefit on First-line Palbociclib + ET

Released: June 09, 2023

Activity

Progress
1
Course Completed